Some of the legal and regulatory obstacles to value-based contracting between biopharma manufacturers and payers could be cleared with the help of guidance from the HHS Office of Inspector General designating specific safe harbors, Eli Lilly & Co. VP and Deputy General Counsel (USA) Alonzo Weems commented at a recent conference in Washington DC.
“This is one very specific step the OIG can take, to issue new or updated compliance guidance to manufacturers, specifically addressing value-based contracts, specifically addressing what it deems acceptable and...